Ask AI

Next-Generation Approaches for Relapsed/Refractory Multiple Myeloma: A Focus on Novel Therapeutic Targets and Pathways

In this online program based on a symposium from EHA 2025, experts discuss emerging uses of CELMoDs for treating patients with relapsed/refractory multiple myeloma. Download slides, view an on-demand webcast, and read an expert commentary for more information on this topic.

Share

Program Content

Events

Activities

Novel Protein Degraders for MM
Key Data and Ongoing Trials With Novel Protein Degraders in Multiple Myeloma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2025

Expires: June 10, 2026

Novel Approaches to MM Treatment
Next-Generation Approaches for Relapsed/Refractory Multiple Myeloma: A Focus on Novel Protein Degraders
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2025

Expires: June 10, 2026

Protein Degradation in MM
The Rationale for Targeting Protein Degradation Pathways in Myeloma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: June 11, 2025

Expires: June 10, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb